cure after tonsillectomy Periodic clinical signs; persistent over years; no response to antibiotics; increased proinflammatory cytokine levels during flares; responsive to corticosteroids ...
The US regulator has said it hopes to give Novartis' Ilaris (canakinumab) a fast review in three types of Periodic Fever Syndromes, after granting it Breakthrough Therapy status in these new uses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback